Company intelligence / Profile preview

oncgnostics GmbH

Jena, Thuringia, Germanyoncgnostics.com ↗

Ownership: Private
Development stage: Commercial

Overview

GynTect®, their molecular biological test for cervical cancer, has been on the market since 2015. The company is also developing tests for head and neck tumors and ovarian cancer.

Therapeutic areas: Oncology
Modalities: In vitro diagnostic tests
Industry: Molecular Diagnostics

Drug pipeline

1 asset

GynTect

Commercial

Indications: Cervical cancer

Partnerships

University Women's Hospital Jenainternational partners (specific names not provided)

Beyond the preview

Go deeper on oncgnostics GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oncgnostics GmbH.

Explore the full profile